alpha Linolenic acid / Bcl-2 Cancer Research Results

aLinA, alpha Linolenic acid: Click to Expand ⟱
Features:

alpha Linolenic acid — Alpha-linolenic acid is an essential plant-derived omega-3 polyunsaturated fatty acid (PUFA; 18:3n-3) found in flax/chia, walnuts, and certain vegetable oils. It is a dietary lipid nutrient (not a regulated anticancer drug) and a metabolic precursor that can be elongated/desaturated to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), albeit inefficiently in most adults. Standard abbreviation: ALA (clarify vs “alpha-lipoic acid,” which is also abbreviated ALA in some contexts).

Primary mechanisms (ranked):

  1. Membrane phospholipid incorporation and lipid microdomain remodeling (raft-dependent signaling context-dependent)
  2. Eicosanoid and specialized pro-resolving mediator tone shift via ω-6/ω-3 substrate competition and partial conversion to EPA/DHA
  3. Inflammatory signaling modulation (e.g., NF-κB/cytokine tone; context- and tissue-dependent)
  4. PPAR signaling and lipid-metabolic reprogramming (context-dependent; often stronger for EPA/DHA than for ALA itself)
  5. Redox biology effects dominated by PUFA peroxidation susceptibility (secondary; can be protective or injurious depending on antioxidant context)

Bioavailability / PK relevance: Absorbed as a dietary fat (enhanced with meals) and incorporated into circulating lipids and cell membranes; systemic biology is dominated by tissue incorporation plus limited bioconversion. Adult conversion of ALA to EPA is typically in the single-digit to low-teens percent range, while DHA conversion is usually <1% (variable by sex, baseline diet, and competing linoleic acid intake).

In-vitro vs systemic exposure relevance: Many mechanistic “direct anticancer” effects reported in cell culture use supraphysiologic free-fatty-acid conditions (often albumin-poor) that can exaggerate lipotoxicity and lipid-peroxidation stress; in vivo effects are more plausibly mediated by membrane remodeling and lipid-mediator shifts rather than acute cytotoxicity.

Clinical evidence status: Human evidence is strongest for cardiometabolic endpoints and mortality associations; oncology-specific evidence for ALA as an anticancer intervention is limited and heterogeneous (mostly observational). Meta-analyses report mixed signals for cancer risk (including historical concern for prostate cancer in some datasets), and omega-3 supplementation trials overall have not shown clear reductions in cancer incidence; ALA-specific RCT evidence for cancer outcomes remains sparse.

Alpha Linolenic acid naturally-occurring fatty acid. Found in vegetable oils, plant oils, nuts and meat.
• Alpha linolenic acid (ALA) is an essential omega-3 fatty acid commonly found in plant sources such as flaxseed, chia seeds, walnuts, and certain vegetable oils.
• As an essential fatty acid, ALA must be obtained from the diet and serves as a precursor to longer-chain omega-3 fatty acids, namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
• While ALA itself is not a strong antioxidant, its downstream metabolites can indirectly support antioxidant defense systems.
• By reducing oxidative stress, ALA may help protect cellular DNA from damage that can trigger carcinogenesis.

Alpha-linolenic acid (ALA) mechanistic axes relevant to cancer biology

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Membrane lipid remodeling and lipid microdomains Growth signaling platforms ↔ (context-dependent); receptor clustering may shift Membrane fluidity ↑ R, G Signal microenvironment modulation Central “direct” mechanism for ALA is incorporation into phospholipids; downstream signaling changes are model- and composition-dependent and may be stronger after partial conversion to EPA.
2 Eicosanoid balance and lipid mediator tone Pro-inflammatory eicosanoids ↓ (context-dependent) Inflammation resolution tone ↑ (context-dependent) G Lipid mediator rebalancing ALA competes with ω-6 substrates and can modestly raise EPA; DHA rise is usually minimal, limiting DHA-linked effects.
3 NF-κB and cytokine signaling NF-κB ↓ or ↔ (model-dependent) Inflammatory tone ↓ (context-dependent) R, G Anti-inflammatory modulation Often secondary to lipid-mediator shifts and membrane effects; direction can vary by cell type and stimulus.
4 PPAR axis and lipid metabolism programs PPAR signaling ↔ or ↑ (context-dependent); lipid metabolism rewiring Metabolic flexibility ↑ G Transcriptional metabolic modulation PPAR effects are well-established for fatty-acid ligands broadly; relative potency may be higher for long-chain ω-3s than for ALA.
5 AMPK and energy-stress signaling AMPK ↑ (context-dependent) Energy homeostasis support ↔ R, G Metabolic checkpoint engagement Reported in some systems, but less consistent than for EPA/DHA; may couple to downstream mTOR tone in select models.
6 PI3K AKT mTOR Survival signaling ↓ (model-dependent) ↔ R, G Growth pathway modulation Usually secondary to membrane composition and inflammatory tone; not a universal primary mechanism.
7 ROS and lipid peroxidation susceptibility ROS ↑ (high concentration only) or ↔; lipid peroxidation ↑ (context-dependent) Oxidative injury ↔ or ↑ (context-dependent) P, R, G Redox stress or redox buffering PUFAs are oxidation-prone; outcomes depend strongly on antioxidant capacity, iron availability, and culture vs in vivo context.
8 Apoptosis and mitochondrial integrity Apoptosis ↑ (model-dependent) ↔ G Cell fate shift Often downstream of membrane/redox changes; direct cytotoxicity is more likely under non-physiologic in-vitro conditions.
9 Angiogenesis and VEGF axis VEGF ↓ (model-dependent) ↔ G Pro-angiogenic signaling dampening Frequently secondary to inflammatory signaling shifts rather than a direct ALA-specific target.
10 HIF-1α and hypoxia programs HIF-1α ↓ (model-dependent) ↔ G Stress-adaptation modulation May track with changes in inflammatory/redox tone; evidence is preclinical and context-sensitive.
11 Chemosensitization Therapy response ↑ (context-dependent) — G Adjunct response modulation Signals exist for ω-3s broadly, but ALA-specific and clinically reproducible effects are uncertain.
12 Clinical Translation Constraint EPA/DHA conversion limited; competing linoleic acid can reduce conversion Diet- and phenotype-dependent exposure — PK and biology constraint Many endpoints attributed to ω-3 biology are driven more robustly by EPA/DHA; ALA’s impact depends on dose, background diet, and individual metabolism.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (lipid incorporation begins; oxidative interactions)
  • R: 30 min–3 hr (early signaling + inflammatory shifts)
  • G: >3 hr (membrane remodeling, phenotype-level effects)

Alpha-linolenic acid (ALA) axes relevant to Alzheimer’s disease biology

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Brain lipid supply and membrane composition ↔ to ↑ (context-dependent) Supports neuronal/glial membrane lipid remodeling ALA is a precursor pool; central effects depend on dietary intake, transport, and limited conversion to EPA/DHA. DHA accretion from ALA is typically minimal in adults.
2 Neuroinflammation and microglial activation tone ↓ or ↔ (context-dependent) Dampens pro-inflammatory signaling in some models Often mediated indirectly via ω-6/ω-3 substrate competition and downstream lipid mediator balance; genotype (e.g., APOE) and baseline diet may modify effects.
3 Blood–brain barrier integrity and neurovascular unit ↑ (context-dependent) Barrier support, vascular inflammation reduction Preclinical and mechanistic literature suggests lipid composition influences BBB properties; clinical specificity for ALA remains uncertain.
4 Aβ production/clearance balance ↔ (model-dependent) Potential shift in amyloidogenic processing or clearance pathways Evidence is heterogeneous; effects reported for ω-3 biology are more consistently linked to DHA/EPA than to ALA per se.
5 Tau phosphorylation and proteostasis stress responses ↔ (model-dependent) Possible modulation of kinase/phosphatase balance and stress signaling Not a well-established primary ALA target; if present, likely secondary to inflammatory/metabolic tone shifts.
6 Brain energy metabolism and insulin signaling ↔ to ↑ (context-dependent) Supports metabolic resilience (glucose handling) in some contexts Human biomarker studies often focus on EPA/DHA; ALA associations may reflect broader dietary patterns and fatty-acid network effects.
7 ROS and lipid peroxidation ↔ (context-dependent); lipid peroxidation risk ↑ (oxidative, low-antioxidant contexts) Shifts ROS production vs oxidation susceptibility ALA can reduce inflammation-linked ROS generation in some settings, but as an unsaturated PUFA it increases oxidizable substrate; net “ROS injury” depends on redox/iron/antioxidant context and whether ALA is membrane-incorporated vs free fatty acid.
8 Synaptic plasticity and neurotransmission support ↔ to ↑ (context-dependent) Potential support for synaptic function via membrane effects More robust evidence exists for DHA in synaptic membranes; ALA may contribute indirectly or in deficiency/low ω-3 states.
9 Clinical Translation Constraint — Exposure and effect-size limitation ALA-specific cognitive/AD trial evidence is limited; conversion to DHA is typically very low, and background linoleic acid intake can reduce long-chain ω-3 formation.


Bcl-2, B-cell CLL/lymphoma 2: Click to Expand ⟱
Source: HalifaxProj (inhibit) CGL-Driver Genes
Type: Antiapoptotic Oncogene
The proteins of BCL-2 family are classified into three subgroups, i.e., the anti-apoptotic/pro-survival proteins represented by BCL-2 and BCL-XL, the pro-apoptotic proteins represented by BAX and Bak, and the pro-apoptotic BH3-only proteins represented by BAD and BID.
Since the expression of Bcl-2 protein in tumor cells is much higher than that in normal cells, inhibitors targeting it have little effect on normal cells.
Scientific Papers found: Click to Expand⟱
1253- aLinA,    The Antitumor Effects of α-Linolenic Acid
- Review, NA, NA
PPARγ↑, COX2↓, E6↓, E7↓, P53↑, p‑ERK↓, p38↓, lipid-P↑, ROS⇅, MPT↑, MMP↓, Cyt‑c↑, Casp↑, iNOS↓, NO↓, Casp3↑, Bcl-2↓, Hif1a↓, FASN↓, CRP↓, IL6↓, IL1β↓, IFN-γ↓, TNF-α↓, Twist↓, VEGF↓, MMP2↓, MMP9↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

lipid-P↑, 1,   ROS⇅, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,   MPT↑, 1,  

Core Metabolism/Glycolysis ⓘ

FASN↓, 1,   PPARγ↑, 1,  

Cell Death ⓘ

Bcl-2↓, 1,   Casp↑, 1,   Casp3↑, 1,   Cyt‑c↑, 1,   iNOS↓, 1,   p38↓, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↓, 1,  

Migration ⓘ

MMP2↓, 1,   MMP9↓, 1,   Twist↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,   NO↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   CRP↓, 1,   IFN-γ↓, 1,   IL1β↓, 1,   IL6↓, 1,   TNF-α↓, 1,  

Clinical Biomarkers ⓘ

CRP↓, 1,   E6↓, 1,   E7↓, 1,   IL6↓, 1,  
Total Targets: 30

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Bcl-2, B-cell CLL/lymphoma 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:116  Target#:27  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page